149 related articles for article (PubMed ID: 37675959)
1. Net clinical benefit of dual antiplatelet therapy in elderly patients with acute coronary syndrome: A systematic review and meta-analysis.
Fujisaki T; Kuno T; Iwagami M; Miyamoto Y; Takagi H; Deharo P; Cuisset T; Briasoulis A; Panaich S; Latib A; Kohsaka S
Catheter Cardiovasc Interv; 2023 Nov; 102(5):788-802. PubMed ID: 37675959
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
Kuno T; Fujisaki T; Shoji S; Sahashi Y; Tsugawa Y; Iwagami M; Takagi H; Briasoulis A; Deharo P; Cuisset T; Latib A; Kohsaka S; Bhatt DL
Circ Cardiovasc Interv; 2022 Aug; 15(8):e011990. PubMed ID: 35899618
[TBL] [Abstract][Full Text] [Related]
3. Strategy of dual antiplatelet therapy for patients with ST-elevation myocardial infarction and non-ST-elevation acute coronary syndromes: A systematic review and network meta-analysis.
Saito T; Fujisaki T; Aikawa T; Kampaktsis PN; Malik A; Briasoulis A; Takagi H; Wiley J; Slipczuk L; Kuno T
Int J Cardiol; 2023 Oct; 389():131157. PubMed ID: 37433404
[TBL] [Abstract][Full Text] [Related]
4. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
[TBL] [Abstract][Full Text] [Related]
5. Short-Term DAPT and DAPT De-Escalation Strategies for Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Kuno T; Watanabe A; Shoji S; Fujisaki T; Ueyama H; Takagi H; Deharo P; Cuisset T; Bangalore S; Mehran R; Stone GW; Kohsaka S; Bhatt DL
Circ Cardiovasc Interv; 2023 Sep; 16(9):e013242. PubMed ID: 37609850
[TBL] [Abstract][Full Text] [Related]
6. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.
Tavenier AH; Mehran R; Chiarito M; Cao D; Pivato CA; Nicolas J; Beerkens F; Nardin M; Sartori S; Baber U; Angiolillo DJ; Capodanno D; Valgimigli M; Hermanides RS; van 't Hof AWJ; Ten Berg JM; Chang K; Kini AS; Sharma SK; Dangas G
Eur Heart J Cardiovasc Pharmacother; 2022 Aug; 8(5):492-502. PubMed ID: 34459481
[TBL] [Abstract][Full Text] [Related]
7. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis.
Kang J; Rizas KD; Park KW; Chung J; van den Broek W; Claassens DMF; Choo EH; Aradi D; Massberg S; Hwang D; Han JK; Yang HM; Kang HJ; Chang K; Ten Berg JM; Sibbing D; Koo BK; Kim HS
Eur Heart J; 2023 Apr; 44(15):1360-1370. PubMed ID: 36883613
[TBL] [Abstract][Full Text] [Related]
8. De-escalation of Antiplatelet Therapy After Percutaneous Coronary Intervention in East Asian Patients With Acute Coronary Syndrome.
Li W; Zhou S; Zhang H; Wang Z; Mu G; Xie Q; Liu Z; Hua M; Cui Y; Xiang Q
Clin Ther; 2024 Feb; 46(2):114-121. PubMed ID: 38071131
[TBL] [Abstract][Full Text] [Related]
9. Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis.
Ullah W; Zahid S; Sandhyavenu H; Faisaluddin M; Khalil F; Pasha AK; Alraies MC; Cuisset T; Rao SV; Sabouret P; Savage MP; Fischman DL
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):717-727. PubMed ID: 35325105
[TBL] [Abstract][Full Text] [Related]
10. Three versus 12-month dual antiplatelet therapy duration in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
Selvaraj V; Chatterjee S; Hirai T; Abbott JD; Bavishi C
Catheter Cardiovasc Interv; 2022 Dec; 100(7):1151-1158. PubMed ID: 36326115
[TBL] [Abstract][Full Text] [Related]
11. Optimal anti-platelet therapy for older patients with acute coronary syndrome: a network meta-analysis of randomized trials comprising 59,284 older patients.
Zhou S; Li W; Xiang Q; Wang Z; Zhang H; Mu G; Liu Z; Cui Y
J Thromb Thrombolysis; 2024 Jan; 57(1):143-154. PubMed ID: 37548902
[TBL] [Abstract][Full Text] [Related]
12. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF
Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233
[TBL] [Abstract][Full Text] [Related]
13. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis.
Khan SU; Singh M; Valavoor S; Khan MU; Lone AN; Khan MZ; Khan MS; Mani P; Kapadia SR; Michos ED; Stone GW; Kalra A; Bhatt DL
Circulation; 2020 Oct; 142(15):1425-1436. PubMed ID: 32795096
[TBL] [Abstract][Full Text] [Related]
14. Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.
Laudani C; Greco A; Occhipinti G; Ingala S; Calderone D; Scalia L; Agnello F; Legnazzi M; Mauro MS; Rochira C; Buccheri S; Mehran R; James S; Angiolillo DJ; Capodanno D
JACC Cardiovasc Interv; 2022 Feb; 15(3):268-277. PubMed ID: 35144783
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Misumida N; Abo-Aly M; Kim SM; Ogunbayo GO; Abdel-Latif A; Ziada KM
Clin Cardiol; 2018 Nov; 41(11):1455-1462. PubMed ID: 30225978
[TBL] [Abstract][Full Text] [Related]
16. Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial.
Orban M; Trenk D; Geisler T; Rieber J; Hadamitzky M; Gross L; Orban M; Kupka D; Baylacher M; Müller S; Huber K; Koltowski L; Huczek Z; Heyn J; Jacobshagen C; Aradi D; Massberg S; Sibbing D; Hein R;
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):372-381. PubMed ID: 31855244
[TBL] [Abstract][Full Text] [Related]
17. De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Shoji S; Kuno T; Fujisaki T; Takagi H; Briasoulis A; Deharo P; Cuisset T; Latib A; Kohsaka S
J Am Coll Cardiol; 2021 Aug; 78(8):763-777. PubMed ID: 34275697
[TBL] [Abstract][Full Text] [Related]
18. De-escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: An Updated Meta-analysis and Trial Sequential Analysis of 21 Studies and 38,741 Patients.
Hu MJ; Tan JS; Gao XJ; Yang JG; Yang YJ
J Cardiovasc Pharmacol; 2022 Jun; 79(6):873-886. PubMed ID: 35500147
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
20. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
